Marker Therapeutics (MRKR) Stock: Buy, Sell, or Hold?
MRKR - Marker Therapeutics, Inc. Common Stock
$1.07
-0.06 (-5.31%)
âŧ
5d:
+16.3%
30d:
-13.71%
90d:
-12.3%
WAIT
LOW Confidence
Analysis Updated: Oct 21, 2026 12:00 AM ET
Earnings: Nov 12, 2026
20d
Get Alerted When MRKR Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: MRKR is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: MRKR is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
In-depth Analysis How we analyze
Valuation Analysis: MRKR is currently trading at $1.07, which is considered fair relative to its 30-day fair value range of $0.99 to $1.19.
Technical Outlook: Technically, MRKR is in a downtrend. Immediate support is located at $0.88, while resistance sits at $1.27. Short-term momentum is weak, with the stock down 5.3% recently.
Market Sentiment: The stock scores a mixed 42/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $7.87 (+635.2%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, MRKR is in a downtrend. Immediate support is located at $0.88, while resistance sits at $1.27. Short-term momentum is weak, with the stock down 5.3% recently.
Market Sentiment: The stock scores a mixed 42/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $7.87 (+635.2%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$0.99 -
$1.19
Company Quality Score
49/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
69.5%
All Signals
- NEUTRAL: Price in fair range
- NEUTRAL: Mixed technical signals (42/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-5.3%)
- BULLISH: Trading 635.2% below Wall St target ($7.87)
- WARNING: Composite score 49/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$0.99 -
$1.19
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$0.88
Resistance Level
$1.27
Current Trend
Downtrend
Technical data as of
Oct 22, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-2.02
Wall Street Target
$7.87
(+635.2%)
Revenue Growth (YoY)
-51.0%
Profit Margin
-245.5%
Share & Embed Analysis
Last updated: October 22, 2026 6:06 PM ET
Data refreshes hourly during market hours. Next update: 7:06 PM
Data refreshes hourly during market hours. Next update: 7:06 PM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is MRKR showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
VRTX
Vertex Pharmaceuticals IâĻ |
STRONG BUY
32 analysts |
$571 | 49 HOLD |
|
ALNY
Alnylam Pharmaceuticals âĻ |
STRONG BUY
30 analysts |
$369 | 50 HOLD |
|
ONC
BeiGene, Ltd. |
STRONG BUY
27 analysts |
$436 | 39 SELL |
|
ASND
Ascendis Pharma AS |
STRONG BUY
21 analysts |
$307 | 51 HOLD |
|
RYTM
Rhythm Pharmaceuticals IâĻ |
STRONG BUY
18 analysts |
$144 | 70 BUY |
